LIVE POLIO IRUS VACCINES

More documents

Recommendations

Info

_llmrr//lnlllllllllllllllllllillllllllll lnlll1TmlllIllrilllllllrmllllllnllllll SEVENTH SESSION THURSDAY, 9 JUNE 1960, 9:00 A.M. O1111111111111111111lllllillllUlrrllllll 1111·····11··r·1·11-·11111···.···1·1···1 · ·····ml·11·lilmmrmnrrmrniiniiiiiiiimiiiiim iiimiiiiiiiiiiiiiimniiiiiiiiiiillniiiiTm Chairman DR. ANDREW J. RHODES Director, School of Hygiene University of Toronto Toronto. Canada TOPIC III. EFFICACY. (B) FIELD EVIDENCE (continuation) Presentation o! Papers by: Dr. M. E. Flipse Dr. G. M. Erickson (DISCUSSION) Dr. Stanley A. Plotkin Dr. James H. S. Gear (DISCUSSION) Dr. A. A. Smorodintsev 433
Page 1 and 2:
LIVE POLIO IRUS VACCINES Papers Pre
Page 3 and 4:
SECOND INTERNATIONAL CONFERENCE ON
Page 5:
Preface The accumulation of informa
Page 8 and 9:
Page Discussion .......... .......
Page 10 and 11:
Page 6. Vaccination of Full-Term In
Page 12 and 13:
Page 23. Vaccination against Poliom
Page 14 and 15:
Dr. Ghislain COURTOIS Director, Pri
Page 16 and 17:
Dr. Edith PETTE Institute for the R
Page 18:
imimmmmmñimmimmm-ñmñmñrmimmimmm
Page 21 and 22:
4 Introductory Remarks 4 Introducto
Page 23 and 24:
6 General Considerations immunity a
Page 25 and 26:
8 General Considerations from accep
Page 27 and 28:
10 General Considerations 10 Genera
Page 29 and 30:
_nTlmmlllllTlllllllnT/I1T~lllmlimll
Page 31 and 32:
14 Safety-Laboratory Evidence of At
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
- 26 Safety-Laboratory Evidence of
Page 45 and 46:
DISCUSSION CHAIRMAN ANDERSON: There
Page 47 and 48:
30 Discussion CHAIRMAN ANDERSON: Th
Page 49 and 50:
32 TABLE 1. Safety-Laboratory Evide
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
40 Discussion Of the 22 monkeys inf
Page 59 and 60:
Page 61 and 62:
DISCUSSION CHAIRMAN ANDERSON: Thank
Page 63 and 64:
46 Discussion a paralytic case. Thi
Page 65 and 66:
48 Discussion + - + + I + - I + + 1
Page 67 and 68:
50 Discussion sages of neurovirulen
Page 70 and 71:
UUYaYLlrmUIIIIIIYYIi1IYllllliTI11II
Page 72 and 73:
Application of Genetic Markers to D
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Discussion 67 TABLE 1. INCIDENCE OF
Page 86 and 87:
Experimental Studies on Animals wit
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
6. DETECTION OF A "NON-DETECTABLE"
Page 98 and 99:
Detection of a "Non-Detectable" Sim
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Discussion 87 Dr. Koprowski's state
Page 106 and 107:
Discussion 89 recognize its effects
Page 108 and 109:
Laboratory Investigations of Attenu
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Discussion 99 In the case of Table
Page 118 and 119:
8. BEHAVIOR OF COLD MUTANTS OF POLI
Page 120 and 121:
Behavior of Cold Mutants of Poliovi
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
DISCUSSION CHAIRMAN BURNET: Thank y
Page 128:
IULUUmmiillaYIIiiiiIllnllTrTnTnTm T
Page 131 and 132:
114 Safety-Field Evidence of Safety
Page 133 and 134:
Page 135 and 136:
118 S afety-Field Evidence of S af
Page 137 and 138:
Page 139 and 140:
122 Discussion 122 Discussion~~~~~~
Page 141 and 142:
10. LABORATORY INVESTIGATIONS OF TH
Page 143 and 144:
126 VIRUS 1 MAhONEY Safety-Field Ev
Page 145 and 146:
128 Safety-Field Evidence óf Safet
Page 147 and 148:
Page 149 and 150:
DISCUSSION CHAIRMAN ZHDANOV: This p
Page 151 and 152:
11. EPIDEMIOLOGICAL AND VIROLOGICAL
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
12. SPREAD OF A VACCINE STRAIN OF P
Page 163 and 164:
Page 165 and 166:
148 Saf ety-Field Evidence of Saf e
Page 167 and 168:
Page 169 and 170:
152 Saf ety-Field Evidence of Safet
Page 171 and 172:
Page 173 and 174:
DISCUSSION CHAIRMAN ZHDANOV: The pa
Page 175 and 176:
158 Discussion 158 Díscussion~~~~~
Page 177 and 178:
160 Discussion specimens. We were u
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
. . . 168 Safety-Field Evidence of
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
14. THE CAPACITY OF LIVE ATTENUATED
Page 193 and 194:
176 Saf ety-Field Evidence of Saf e
Page 195 and 196:
... ____ v __ _"_ _. ___.__ __ .,_.
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 204 and 205:
"""lliiiiirmlilrrmiiiiiiiii iiiii,,
Page 206 and 207:
Field, Laboratory Experiences With
Page 208 and 209:
16. STUDIES ON LIVE POLIOVIRUS VACC
Page 210 and 211:
Studies on Live Poliovirus Vaccine
Page 212 and 213:
; _ o - -01 1 0 h 4.cccM oe u, Co F
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Da. HORSTMANN: If I may answer for
Page 222 and 223:
Discussion 205 Discussion 205 tried
Page 224 and 225:
NOTE: The Spanish translation of th
Page 226 and 227:
Vaccination of Pregnant Women and Y
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
Development and Persistence of Poli
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Page 256 and 257:
Page 258 and 259:
Virologic, Serologic Investigations
Page 260 and 261:
Page 262 and 263:
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
Page 270 and 271:
Page 272 and 273:
Page 274 and 275:
Page 276 and 277:
Page 278 and 279:
Page 280 and 281:
_ _ _ _ _ _ _ _ Virologic, Serologi
Page 282 and 283:
Page 284 and 285:
cARE NUC:4I Discussion 267 CUAw # J
Page 286 and 287:
Discussion 269 in the investigation
Page 288 and 289:
Virological Findings, Antibody Resp
Page 290 and 291:
Page 292 and 293:
Page 294 and 295:
4. ROUTINE IMMUNIZATION WITH ATTENU
Page 296 and 297:
Routine Immunization With Attenuate
Page 298 and 299:
Page 300:
Page 304 and 305:
mmrriiiiiiiiiiiinniiiiiiiriiimmmmmn
Page 306 and 307:
Experimental Infectionwith CHATAtte
Page 308 and 309:
Experimental Infection with CHATAtt
Page 310 and 311:
Experimental Infection with CHATAtt
Page 312 and 313:
Vaccination of Full-Term Infants wi
Page 314 and 315:
Page 316 and 317:
Page 318 and 319:
Page 320 and 321:
Response of Newborn Infants to Vacc
Page 322 and 323:
Page 324 and 325:
Page 326 and 327:
Susceptibility of Newborn Infants t
Page 328 and 329:
Page 330 and 331:
Page 332 and 333:
9. IMMUNIZATION OF NEWBORN INFANTS
Page 334 and 335:
Immunization of Newborn Infants wit
Page 336 and 337:
Page 338 and 339:
Page 340 and 341:
Discussion 323 vaccinated siblings
Page 342 and 343:
Discussion 325 Discussion 325 ance
Page 344 and 345:
transplacental antibodies, or antib
Page 346 and 347:
Discussion 329 Discussion 329 born
Page 348 and 349:
Recent Experience with Lederle Triv
Page 350 and 351:
Page 352 and 353:
Page 354 and 355:
Page 356 and 357:
Page 358 and 359:
11. FURTHER EXPERIENCES WITH ORAL P
Page 360 and 361:
Further Experiences with Oral Polio
Page 362 and 363:
Page 364 and 365:
Page 366 and 367:
Page 368 and 369:
Page 370:
Page 374 and 375:
_1111_11111111111111llllIllllllllll
Page 376 and 377:
Minnesota Studies with Oral Poliomy
Page 378 and 379:
Page 380 and 381:
Page 382 and 383:
13. USE OF ATTENUATED LIVE POLIOVIR
Page 384 and 385:
Use of Attenuated Live Poliovirus V
Page 386 and 387:
Use of Attenuated Live Poliovirus V
Page 388 and 389:
DISCUSSION CHAIRMAN LÉPINE: The tw
Page 390 and 391:
Discussion 373 -~~~~~~ics o 7 domin
Page 392 and 393:
Discussion 375 -~ ~~~~isuso 7 DR. C
Page 394 and 395:
i 14. EFFECTS OF RAPID MASS IMMUNIZ
Page 396 and 397:
Live Poliovirus Immunization-Condit
Page 398 and 399:
Live Poliovirus Immunization-Condit
Page 400 and 401: Live Poliovirus Immunization-Condit
Page 402 and 403: Live Poliovirus Immunization-Condit
Page 404 and 405: Use of Sabin's Live Poliovirus Vacc
Page 410 and 411: - Use of Sabin's Live Poliovirus Va
Page 414 and 415: TABLE 14. Use of Sabin's Live Polio
Page 428 and 429: Discussion 411 DR. ANDERSON: My que
Page 430 and 431: llllllmlllllmlllllI 1111111111··
Page 432 and 433: Course of Mass Immunization in USSR
Page 440 and 441: , _ _ Course of Mass Immunization i
Page 446 and 447: DISCUSSION CHAIRMAN LÉPINE: Thank
Page 448 and 449: Discussion 431 DR. STUART-HARRIS: I
Page 452 and 453: lilllmlllllll'll1lllllilrrmllllllll
Page 454 and 455: Large-Scale Field Trial with Oral C
Page 462 and 463: 18. PRELIMINARY REPORT OF EPIDEMIOL
Page 464 and 465: Epidemiological Surveillance in Mas
Page 474 and 475: DISCUSSION CHAIRMAN RHODES: These t
Page 476 and 477: Discussion 459 -~~~~Dsuso 5 We did
Page 478 and 479: Discussion 461 logical anomalies of
Page 480 and 481: Discussion 463 The majority of chil
Page 482: case of poliomyelitis, if it was po
Page 485 and 486: 468 Efficacy-Field Evidence TABLE 4
Page 487 and 488: 470 Efficacy-Field Evidence 470 Eff
Page 491 and 492: 20. LIVE VIRUS VACCINE STUDIES IN S
Page 497 and 498: DISCUSSION CHAIRMAN RHODES: These t
Page 499 and 500: 21. MATERIAL ON THE IMMUNOLOGICAL A
Page 501 and 502:
484 Efficacy-Field Evidence 484 Efi
Page 503 and 504:
486 Efficacy-Field Evidence 486 iEf
Page 505 and 506:
488 Efficacy-Field Evidence - TABLE
Page 507 and 508:
490 Efficacy-Field Evidence TABLE 4
Page 509 and 510:
Page 511 and 512:
494 Efficaey-Field Evidence TABLE 9
Page 513 and 514:
496 Efficaey-Field Evidence TABLE 1
Page 515 and 516:
498 Efficacy-Field Evidence Qo - Co
Page 517 and 518:
500 Etfficacy-Field Evidence 500 Ef
Page 520:
lmllliiimlll1llrrmmIiiiiiiiiiiiiii,
Page 523 and 524:
506 Discussi on hausted the morbidi
Page 525 and 526:
Page 527 and 528:
510 Efficacy-Field Evidence b 'r3 `
Page 529 and 530:
512 ol o c,- 4 3- 0 7 Efficacy-Fiel
Page 531 and 532:
514 Efficacy-Field Evidence b, U *
Page 533 and 534:
516 Efficacy-Field Evidence o e 0 1
Page 535 and 536:
518 Efficacy-Field Evidence in the
Page 537 and 538:
520 Efficacy-Field Evidence thing w
Page 539 and 540:
23. VACCINATION AGAINST POLIOMYELIT
Page 541 and 542:
Page 543 and 544:
Page 545 and 546:
528 Efficacy-Field Evidence MAP 2.
Page 547 and 548:
Page 549 and 550:
DISCUSSION CHAIRMAN STUART-HARRIS:
Page 551 and 552:
534 Efficacy-Field Evidence a still
Page 553 and 554:
536 Efficacy-Field Evidence frigera
Page 555 and 556:
538 TABLE 3. Efficacy-Field Evidenc
Page 557 and 558:
540 Efficacy-Field Evidence sented
Page 559 and 560:
Page 561 and 562:
544 Efficacy-Field Evidence Antibod
Page 563 and 564:
546 Efficacy-Field Evidence 250t 20
Page 565 and 566:
Page 567 and 568:
550 Efficacy-Field Evidence FIGURE
Page 569 and 570:
552 Efficacy-Field Evidence u o o
Page 571 and 572:
-Y 554 Efficacy-Field Evidence TABL
Page 573 and 574:
556 -- Efficacy-Field Evidence 0
Page 575 and 576:
c 558 Efficacy-Field Evidence o z o
Page 577 and 578:
560 Efficacy-Field Evidence Clayton
Page 579 and 580:
562 Efficacy-Field Evidence 2. Triv
Page 581 and 582:
564 Efficacy-Field Evidence and by
Page 583 and 584:
566 Efficacy-Field Evidence establi
Page 585 and 586:
568 Efficacy-Field Evidence Costa R
Page 587 and 588:
570 Efficacy-Fi eld Evidence Two su
Page 589 and 590:
572 Efficacy-Field Evidence o0 u p
Page 591 and 592:
DISCUSSION CHAIRMAN STUART-HARRIS:
Page 593 and 594:
27. LARGE-SCALE PRACTICAL TRIALS AN
Page 595 and 596:
578 Efficacy-Field Evidence some of
Page 597 and 598:
580 Efficacy-Field Evidence vaccine
Page 599 and 600:
582 Efficacy-Field Evidence more th
Page 601 and 602:
584 Efficacy-Field Evidence medical
Page 603 and 604:
586 Efficacy-Field Evidence immuniz
Page 605 and 606:
588 Efficacy-Field Evidence nationa
Page 608 and 609:
DISCUSSION CHAIRMAN VARGAS-MÉNDEZ:
Page 610 and 611:
Discussion 593 -~~~~~isuso 9 a stoo
Page 612 and 613:
Discussion 595 If the chain of tran
Page 614 and 615:
dence of immunization within a few
Page 616 and 617:
Discussion 599 the people in a few
Page 618 and 619:
Summary of the Conference 601 prese
Page 620:
The occurrence of poliomyelitis in
Page 624 and 625:
INDEX Abad Gómez, Héctor, 369 Abo
Page 626 and 627:
Index 609 Attack rates-continued hi
Page 628 and 629:
Index 611 Chromatography purificati
Page 630 and 631:
Index 613 Dosage-continued statisti
Page 632 and 633:
Index 615 Field trials-continued Le
Page 634 and 635:
Index 617 Human tissue-culture syst
Page 636 and 637:
Index 619 Intestinal tract-continue
Page 638 and 639:
Index 621 Markush, R. E., paper 435
Page 640 and 641:
Index 623 Newborns-continued degree
Page 642 and 643:
Index 625 Poliomyelitis, paralytic-
Page 644 and 645:
Index 627 Reversion dangers of, 485
Page 646 and 647:
Index 629 Spread-continued in the c
Page 648 and 649:
Index 631 Vaccination-continued rep
Page 650 and 651:
Index 633 Vaccine, Attenuated, Triv
show all

LIVE POLIO IRUS VACCINES

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?